Close menu

July 21st, 2022 | 11:24 CEST

Time is of the essence! Bavarian Nordic, XPhyto, Valneva

  • Biotechnology
  • Covid19
Photo credits:

Resourceful investors always bet on corresponding stocks when new pathogens or disease patterns become known. BioNTech was one of the early movers in the case of COVID-19, but so were several other stocks that are now unknown again. Even for monkeypox, there have long been stocks that have profited - for example, the share of smallpox vaccine manufacturer Bavarian Nordic which recently rose sharply. We explain the hype around pharmaceutical stocks and outline where there could still be potential now.

time to read: 3 minutes | Author: Nico Popp
ISIN: BAVARIAN NOR NAM. DK 10 | DK0015998017 , XPHYTO THERAPEUTICS | CA98421R1055 , VALNEVA SE EO -_15 | FR0004056851

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    Bavarian Nordic breaks out!

    Yesterday, the Bavarian Nordic share surged toward the EUR 40 mark. Previously, the value had long hovered around EUR 30. What happened? The German-Danish manufacturer of smallpox vaccines announced a new order. Another 1.5 million doses of the vaccine Imvanex are to go to a European country. The Company had already received orders from the US and Canada, which should positively impact the coming fiscal year. In recent weeks and months, Bavarian Nordic has raised its guidance for the current fiscal year several times.

    If the new monkeypox business is not a one-off but also provides support for the coming financial year, this will be positive for Bavarian Nordic's share price - the share price was significantly higher a year ago and therefore has catch-up potential. Weeks ago, pharmacologist Dr Moutih Raffei commented on the danger of the new pathogen and urged hygiene measures: "Transmission from person to person is only likely if symptoms are present. In addition to weeping blisters and skin irritations, the classic droplet infection also plays a role. In regions where infections with monkeypox are likely, I advise the FFP2 mask," the expert said. With more and more cases, it is also likely that more countries will prepare for the danger and order vaccines. For Bavarian Nordic, that means a tailwind.

    XPhyto: Will the opioid epidemic in the US provide a breakthrough?

    A plague of a very different caliber is the abuse of opioids in the US. In 2019, the number of youth and adults with opioid use disorder was estimated to be between 6.7 and 7.6 million. The recognized medical condition is increasingly becoming socially explosive in the United States. Entire swaths of the country are scarred by the widespread addiction and its accompanying symptoms. In order to combat the addiction, drugs such as buprenorphine are used in the US. The National Food and Drug Administration (FDA) is now warning of the serious health consequences of these medications for opioid addiction. Because many of these drugs dissolve in the mouth, tooth decay, cavities, oral infections, and tooth loss can occur.

    Around the latter set of conditions, biotech company XPhyto has long positioned itself to offer several products for the diagnosis of oral and dental diseases, such as stomatitis, periodontitis and peri-implantitis, as part of its biosensor portfolio. Most recently, XPhyto announced plans to evaluate the ability of its products to diagnose concomitant symptoms of buprenorphine. XPhyto's biosensors are self-applying and inexpensive. Given the large number of potential patients in the US alone, XPhyto's products could see increasing demand. In addition to oral and dental disease, XPhyto is also developing biosensors around Group A Streptococcus, Influenza A and COVID-19, addressing a market that is expected to reach approximately USD 42 billion by 2027, according to market researchers such as Global Market Insights. XPhyto's stock is currently trading near its lows. However, if the Company lands a complete success with one of its products, this should change given the market capitalization of around EUR 22 million. The share is very speculative but also exciting.

    Valneva: Patience is needed here

    The development of Valneva shows that the path to success for biotech companies is sometimes rocky. A few weeks ago, the vaccine company announced the entry of Pfizer - the share price almost doubled. Many market participants sensed a complete takeover. But the excitement has died down, and the stock has come back significantly. And this is even though the EU approved Valneva's COVID-19 vaccine in the summer. Hopes are now pinned on the planned Lyme disease vaccine, which has prompted Pfizer to invest in Valneva. However, it will probably be some time before the results are published.

    Whether it is COVID-19, Lyme disease, monkeypox or the indirect effects of the opioid epidemic in the US - anyone who wants to invest in developing medical emergencies and back companies that are fighting these emergencies must have a good hand. Sometimes active ingredients do not even get off the ground; other times, the competition is faster. XPhyto may have found an interesting niche with its biosensors. If, in addition, a test is medically indicated because the drug authority warns of side effects, as is currently the case in the US, this could be the initial spark. The XPhyto share, therefore, belongs on every speculative watch list.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?


    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.


    Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST

    Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar

    • Pharma
    • Biotechnology
    • Innovations

    Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.